Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme

被引：0

作者：

van der Woude, J. ^{[1
]}

Schreiber, S. ^{[2
]}

Peyrin-Biroulet, L. ^{[3
]}

Szekanecz, Z. ^{[4
]}

Choy, E. H. ^{[5
]}

Stiers, P. J. ^{[6
]}

Van Hoek, P. ^{[7
]}

Van Beneden, K. ^{[8
]}

de Haas, A. ^{[9
]}

Rudolph, C. ^{[10
]}

ten Cate, H. ^{[11
]}

机构：

[1] Erasmus Med Ctr Hosp, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

[2] Univ Hosp Schleswig Holstein, Dept Med 1, Kiel, Germany

[3] Univ Hosp Nancy, Div Gastroenterol, Vandoeuvre Les Nancy, France

[4] Univ Debrecen, Dept Rheumatol, Fac Med, Debrecen, Hungary

[5] Cardiff Univ, Sch Med, CREATE Ctr Sect Rheumatol, Div Infect & Immun, Cardiff, Wales

[6] Galapagos NV, Biostat Dept, Mechelen, Belgium

[7] Galapagos NV, Clin Dev Dept, Mechelen, Belgium

[8] Galapagos NV, Med Affairs Dept, Mechelen, Belgium

[9] Galapagos NV, Clin Dev Dept, Leiden, Netherlands

[10] Galapagos NV, Med Affairs Dept, Leiden, Netherlands

[11] Maastricht Univ, Dept Internal Med, Med Ctr, Maastricht, Netherlands

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P520

引用

页码：646 / 648

页数：4

共 50 条

[1] Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme
Limdi, Jimmy
van der Woude, C. Janneke
Schreiber, Stefan
Peyrin-Biroulet, Laurent
Szekanecz, Zoltan
Choy, Ernest
Stiers, Pieter-Jan
Van Hoek, Paul
Van Beneden, Katrien
de Haa, Angela
Rudolph, Christine
ten Cate, Hugo
GUT, 2023, 72 (SUPPL_2) : A20 - A21
[2] Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes
Mariette, Xavier
Borchmann, Sven
Aspeslagh, Sandrine
Szekanecz, Zoltan
Charles-Schoeman, Christina
Schreiber, Stefan
Choy, Ernest H. S.
Peyrin-Biroulet, Laurent
Schmalzing, Marc
Tanaka, Yoshiya
ten Cate, Hugo
Westhovens, Rene
van der Woude, C. Janneke
Omoruyi, Edmund V. Ekoka
Faes, Margaux
Masior, Tomasz
Van Hoek, Paul
Watson, Chris
Rudolph, Christine
Stallmach, Andreas
RMD OPEN, 2025, 11 (01):
[3] CLINICAL CHARACTERISTICS AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS USING ROMOSOZUMAB
Alsaed, O.
Abdulmomen, I.
Alemadi, S.
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S468 - S469
[4] Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
Troum, Orrin
Duong, Mai
Obermeyer, Katie
Padnick-Silver, Lissa
LaMoreaux, Brian
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 461 - 462
[5] Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
Dougados, Maxime
Charles-Schoeman, Christina
Szekanecz, Zoltan
Giles, Jon T.
Ytterberg, Steven R.
Bhatt, Deepak L.
Koch, Gary G.
Vranic, Ivana
Wu, Joseph
Wang, Cunshan
Kwok, Kenneth
Menon, Sujatha
Connell, Carol A.
Yndestad, Arne
Rivas, Jose L.
Buch, Maya H.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (04) : 575 - 577
[6] Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme
Schreiber, Stefan
Rubin, David T.
Ng, Siew C.
Peyrin-Biroulet, Laurent
Danese, Silvio
Modesto, Irene
Guo, Xiang
Su, Chinyu
Kwok, Kenneth K.
Jo, Hyejin
Chen, Yan
Yndestad, Arne
Reinisch, Walter
Dubinsky, Marla C.
JOURNAL OF CROHNS & COLITIS, 2023, 17 (11): : 1761 - 1770
[7] IMPACT OF BASELINE CARDIOVASCULAR RISK ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
Dougados, M.
Charles-Schoeman, C.
Szekanecz, Z.
Giles, J. T.
Ytterberg, S. R.
Bhatt, D. L.
Koch, G. G.
Vranic, I.
Wu, J.
Wang, C.
Kwok, K.
Menon, S.
Connell, C. A.
Yndestad, A.
Rivas, J. L.
Buch, M. H.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 175 - 176
[8] Association of pulse pressure with risk of major adverse cardiovascular events among cardiovascular outcome trial participants
Agarwal, N.
St Jean, J.
Van Iterson, E. H.
Laffin, L.
EUROPEAN HEART JOURNAL, 2023, 44
[9] Prediction of major adverse cardiovascular events by carotid intimal medial thickness, a clinical trial
Ali, YS
Rembold, KE
Weaver, B
Wills, MB
Tatar, S
Ayers, CR
Rembold, CM
CIRCULATION, 2005, 111 (14) : E195 - E195
[10] Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase
Troum, Orrin M.
Duong, Mai
Obermeyer, Katie
Padnick-Silver, Lissa
Lamoreaux, Brian
RHEUMATOLOGY, 2025,

← 1 2 3 4 5 →